Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI

University of Toronto

$25,000.00

Immune cell-microbiome interactions and Neurodegenerative Diseases

EF 2018-19

Résumé
Neurodegenerative diseases, which include Alzheimer's, Parkinsons, and progressive forms of Multiple Sclerosis, place a heavy burden on Canadians. These diseases are chronic, untreated and devastating for patients and their families. Current therapies aimed at tackling the inflammatory component of these diseases, or mis-folded proteins in the brain, have failed to make a large impact in the clinical presentation of the disease. One thing these diseases have in common is age. Interestingly, age has an effect on the microbiota - the community of microbes that live in our bodies. In particular, as we age, the balance of microbes in our gut can become skewed towards particular microbes and the diversity of the overall microbial community may be affected. Moreover, another outcome of aging is a "leaky gut" whereby microbes and their byproducts can penetrate through the gut and access our blood. We know that the microbiota and microbial byproducts can have a tremendous impact on a cell type called microglia. Microglia are immune cells in the brain that are hyper-sensitive to their environment. They play many roles in maintaining a healthy brain but can also be converted to hyper-activated cells that cause brain damage and neurodegeneration. Our research aims to understand how an imbalanced microbiome and a leaky gut in an aged person promotes the progression of MS disease into a stage that is neurodegenerative through its activities on microglial cells in the brain. If we can understand how this works we can then develop therapies to prevent progressive MS, and also other neurodegenerative diseases whereby microglial cells play a detrimental role.
Programme
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
399117
Name
Gommerman Jennifer L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Immune cell-microbiome interactions and Neurodegenerative Diseases
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Immune System; Microbiome; Microglia; Multiple Sclerosis; Neurodegeneration
Abstract
Neurodegenerative diseases, which include Alzheimer's, Parkinsons, and progressive forms of Multiple Sclerosis, place a heavy burden on Canadians. These diseases are chronic, untreated and devastating for patients and their families. Current therapies aimed at tackling the inflammatory component of these diseases, or mis-folded proteins in the brain, have failed to make a large impact in the clinical presentation of the disease. One thing these diseases have in common is age. Interestingly, age has an effect on the microbiota - the community of microbes that live in our bodies. In particular, as we age, the balance of microbes in our gut can become skewed towards particular microbes and the diversity of the overall microbial community may be affected. Moreover, another outcome of aging is a "leaky gut" whereby microbes and their byproducts can penetrate through the gut and access our blood. We know that the microbiota and microbial byproducts can have a tremendous impact on a cell type called microglia. Microglia are immune cells in the brain that are hyper-sensitive to their environment. They play many roles in maintaining a healthy brain but can also be converted to hyper-activated cells that cause brain damage and neurodegeneration. Our research aims to understand how an imbalanced microbiome and a leaky gut in an aged person promotes the progression of MS disease into a stage that is neurodegenerative through its activities on microglial cells in the brain. If we can understand how this works we can then develop therapies to prevent progressive MS, and also other neurodegenerative diseases whereby microglial cells play a detrimental role.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gommerman, Jennifer L; Dunn, Shannon E; Guttman, David S; MacVicar, Brian A; Montalban, Xavier; Oh, Jiwon; Osborne, Lisa
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Aging~ $25,000~ $0~